Company Encyclopedia
View More
name
Cyclacel Pharma
CYCC.US
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
1.946 T
CYCC.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking351/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-277.85%E
    • Profit Margin-64080.00%E
    • Gross Margin0.00%E
  • Growth ScoreD
    • Revenue YoY-87.50%E
    • Net Profit YoY63.49%B
    • Total Assets YoY-46.26%E
    • Net Assets YoY263.46%A
  • Cash ScoreE
    • Cash Flow Margin-0.16%D
    • OCF YoY-87.50%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio17.50%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Cyclacel Pharmaceuticals: Recent Acquisition Completed

    Cyclacel Pharmaceuticals (CYCC) has completed the acquisition of Fitters Sdn. Bhd., enhancing its portfolio in fire safety and pharmaceuticals. This move aims to create long-term shareholder value. However, CYCC faces financial challenges, with operational inefficiencies and a low financial performance score. Spark's analysis rates CYCC as an Underperform, citing unattractive valuation metrics, including a negative P/E ratio and no dividend yield. The current market cap stands at $14.25M, with a strong sell technical sentiment.

    Tip Ranks·
    US
    CYCC
    0.00%
    Tip Ranks·
    US
    CYCC
    0.00%

    Bio Green Med Solution, Inc. has closed the acquisition of Fitters Sdn. Bhd, formerly Cyclacel Pharmaceuticals, Inc.

    Bio Green Med Solution, Inc., previously known as Cyclacel Pharmaceuticals, Inc., has successfully completed the acquisition of Fitters Sdn. Bhd. This strategic move aims to enhance the company's market presence and offerings. No financial details were disclosed regarding the acquisition.

    Unusual Whales·
    US
    CYCC
    0.00%
    Unusual Whales·
    US
    CYCC
    0.00%

    Kua Khai Loon, 10% Owner, Reports Disposal of Common Shares in Cyclacel Pharmaceuticals Inc

    Kua Khai Loon, a 10% owner of Cyclacel Pharmaceuticals Inc, has reported the disposal of common shares in the company. The full filing is available through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice. The original content was published by Cyclacel Pharmaceuticals Inc via EDGAR on September 10, 2025.

    Reuters·
    US
    CYCC
    0.00%
    US
    BGMS
    +7.69%
    Reuters·
    US
    CYCC
    0.00%
    US
    BGMS
    +7.69%

    Cyclacel Pharmaceuticals Inc. Conducted Virtual Special Meeting of Shareholders

    Cyclacel Pharmaceuticals Inc. held a virtual special meeting of shareholders on September 4, 2025, where several proposals were approved. These included the issuance of common stock to Fitters Parent, a potential issuance of over 20% of outstanding shares, and an amendment to change the corporate name to Bio Green Med Solution, Inc.

    Reuters·
    US
    CYCC
    0.00%
    US
    BGMS
    +7.69%
    Reuters·
    US
    CYCC
    0.00%
    US
    BGMS
    +7.69%

    Cyclacel Pharmaceuticals Inc. Executes Warrant Exchange for 559,395 Shares of Common Stock

    Cyclacel Pharmaceuticals Inc. has executed a Warrant Exchange Agreement on September 4, 2025, with accredited investors, exchanging Series C common stock purchase warrants for 559,395 shares of common stock. The exchange was non-cash and the shares were issued without registration under the Securities Act of 1933, relying on Section 3(a)(9) exemption. The share price was not specified.

    Reuters·
    US
    CYCC
    0.00%
    Reuters·
    US
    CYCC
    0.00%
    © 2025 Longbridge｜Disclaimer